Colesevelam hydrochloride in the management of dyslipidemia

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 3, 2006, Pages 283-291

  Armani, Annemarie ^a   Toth, Peter P ^b,c  

^a Imprint Science   (United States)

^b Sterling Rock Falls Clinic ^*  (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Atherosclerosis; Bile acids; Cholesterol; Colesevelam hydrochloride; Coronary artery disease; Ileal bile acid transporter; Lipoprotein receptor; Low density; Micelles

Indexed keywords

ALLYLAMINE DERIVATIVE; ALPHA TOCOPHEROL; ANION EXCHANGE RESIN; ATORVASTATIN; BILE ACID; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; DIGOXIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PREVALITE; QUINIDINE; SIMVASTATIN; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VITAMIN D; VITAMIN K GROUP; WARFARIN;

ABDOMINAL CRAMP; AREA UNDER THE CURVE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOATING; CANADA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENTEROHEPATIC CIRCULATION; ENVIRONMENTAL FACTOR; EUROPE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; MYALGIA; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; RISK REDUCTION; SECONDARY PREVENTION; SMALL INTESTINE ABSORPTION; STROKE; UNITED STATES; WEAKNESS;

ALLYLAMINE; ANION EXCHANGE RESINS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; PATIENT COMPLIANCE;

EID: 33744481264     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.3.283     Document Type: Article

References (41)

1. American Heart Association. American Heart Association Heart Disease and Stroke Statistics - 2005 Update. Dallas, Texas, USA (2004).
2. Wilson P, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847 (1998).
3. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl. J. Med. 350(15), 1495-1504 (2004).
4. ALLHAT officers and coordinators for the ALLHAT collaborative research group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288, 2998-3007 (2002).
5. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158 (2003) (9364).
6. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630 (2002) (9346).
7. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet 360(9362), 7-22 (2002).
8. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001).
9. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227-239 (2004).
10. Grundy SM, Ahrens EH Jr, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J. Lab. Clin. Med. 78(1), 94-121 (1971).
11. Shepherd J, Packard CJ, Bicker S et al. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N. Engl. J Med. 302(22), 1219-1222 (1980).
12. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251(3), 351-364 (1984).
13. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med. 332(8), 512-521 (1995).
14. Watts GF, Lewis B, Brunt JN et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339, 563-569 (1992) (8793).
15. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323(19), 1289-1298 (1990).
16. Andrade SE, Walker AM, Gottlieb LK et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N. Engl. J. Med. 332(17), 1125-1131 (1995).
17. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin. Pharmacother. 4(5), 779-790 (2003).
18. Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann. Pharmacother. 35(7-8), 898-907 (2001).
19. Donovan JM, Von Bergmann K, Setchell KD et al. Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig. Dis. Sci. 50(7), 1232-1238 (2005).
20. Steinmetz KL. Colesevelam hydrochloride. Am. J. Health Syst. Pharm. 59(10), 932-939 (2002).
21. Davidson MH, Dillon MA, Gordon B et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. 159(16), 1893-1900 (1999).
22. Arrese M, Trauner M, Sacchiero RJ et al. Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. Hepatology 28(4), 1081-1087 (1998).
23. Heller DP, Burke SK, Davidson DM et al. Absorption of colesevelam hydrochloride in healthy volunteers. Ann. Pharmacother. 36(3), 398-403 (2002).
24. Insull W Jr, Toth P, Mullican W et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc. 76(10), 971-982 (2001).
25. Blake GJ, Otvos GJ, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106(15), 1930-1937 (2002).
26. Kuller L, Arnold A, Tracy R et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol. 22(7), 1175-1180 (2002).
27. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 185(2),327-330 (2006).
28. Davidson MH, Toth P, Weiss S et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin. Cardiol. 24(6), 467-474 (2001).
29. Hunninghake D, Insull W, Toth P et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 158(2), 407-416 (2001).
30. Knapp HH, Schrott H, Ma P et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. 110(5), 352-360 (2001).
31. Bays H JM, Abby S, Colesevelam. HCl Added to a Statin: Effects on Lipid Profile and hsCRP. American Heart Association Scientific Sessions. Dallas, TX, USA (2005) (Abstract #1087).
32. Xydakis AM, Guyton JR, Chiou P et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am. J. Cardiol. 94(6), 795-797 (2004).
33. Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am. J. Ther. 12(4), 306-310 (2005).
34. Insert SP, Mosby's Drug Consult.
35. Donovan JM, Stypinski D, Stiles MR et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc. Drugs Ther. 14(6), 681-690 (2000).
36. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin. Pharmacokinet. 43(13), 943-950 (2004).
37. Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 279(18), 1458-1462 (1998)
38. Puleston J, Morgan H, Andreyev J. New treatment for bile salt malabsorption. Gut 54(3), 441-442 (2005).
39. Knox J, Emmons R. Colesevelam for the treatment of bile acid diarrhea induced diarrhea in Crohn's disease: patients intolerant of cholestyramine. Gastroenterology 5, W1399 (2004).
40. Berg C. Use of colesevelam hydrochloride (WelChol™) as a novel therapeutic agent for the managment of refractory pruritus in chronic liver disease. Hepatology 34, 541 (2001).
41. Davidson MH, Dittakavi V, Bandari A et al. Colesevelam HCL decreases atherosclerosis and may activate reverse cholesterol transport in cholesterol fed rabbits. J. Appl. Res. 6, 4-13 (2006).